Sitagliptin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Sitagliptin: From Type 2 Diabetes Mellitus to Opsismodysplasia
One-Sentence Summary
Sitagliptin is a DPP-4 inhibitor originally used to treat type 2 diabetes mellitus. The TxGNN model predicts it may be effective for opsismodysplasia, a rare skeletal dysplasia, but this is a computational prediction only. Currently there are 0 clinical trials and 0 publications supporting this specific indication, so the evidence is very limited.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 diabetes mellitus |
| Predicted New Indication | Opsismodysplasia |
| TxGNN Prediction Score | 98.87% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, sitagliptin belongs to the DPP-4 inhibitor class. Its efficacy in type 2 diabetes is established, and it works by raising active incretin levels to enhance glucose-dependent insulin secretion.
Opsismodysplasia is a rare skeletal dysplasia related to INPPL1, and no established link to DPP-4 inhibition has been identified. The high TxGNN score (0.989) appears to come from relationships within the knowledge graph rather than from independent clinical or biological evidence. Any mechanistic rationale is therefore speculative.
Other top-ranked predictions show the same pattern. Several have identical or near-identical scores (for example, classic stiff person syndrome and focal stiff limb syndrome), and a cluster of localized lipodystrophy conditions scores similarly. This suggests the predictions are driven by shared graph neighbours.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for opsismodysplasia.
Singapore Market Information
Sitagliptin has 20 valid single-ingredient registrations in Singapore, including the original JANUVIA brand, generics, and combinations with metformin. Approved indication text was not available for any of them. The main authorizations are:
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| SIN13257P | JANUVIA 100 mg tablet | Tablet | Organon Pharma (UK) Limited |
| SIN13258P | JANUVIA 50 mg tablet | Tablet | Organon Pharma (UK) Limited |
| SIN13259P | JANUVIA 25 mg tablet | Tablet | Organon Pharma (UK) Limited |
| SIN13442P | JANUMET Tablet 50mg/500mg | Film-coated tablet | MSD International GmbH (Singapore Branch) and others |
| SIN14703P | JANUMET XR Tablet 50mg/1000mg | Extended-release film-coated tablet | MSD International GmbH (Puerto Rico Branch) and others |
Safety Considerations
- Contraindications (knowledge-graph associations, not label text): kidney disease, pancreatitis, liver disease, gallbladder disease, adrenocortical insufficiency, Addison disease, various pituitary hormone deficiencies, hypogonadotropic hypogonadism, thymus gland disease, and infectious disease.
- Drug Interactions: 100 interactions were identified. Most listed ones are Moderate, including phenylephrine, pseudoephedrine, epinephrine, salbutamol, formoterol, acetazolamide, hydrochlorothiazide, estradiol, hydrocortisone, benazepril, aripiprazole, and ethanol. Hydrocortisone (topical) and alclometasone (topical) are Minor.
- Pancreatitis signal: A published case report describes sitagliptin-induced pancreatitis after 8 years of use. This is a safety concern, not supportive evidence.
Please refer to the package insert for full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is based only on a graph model score, with no clinical trials or relevant publications. No mechanistic link between DPP-4 inhibition and opsismodysplasia has been identified. Safety data from the package insert is also not yet available.
To proceed, the following is needed:
- Mechanism of action data for sitagliptin
- Package insert warnings and contraindications from HSA
- Preclinical or biological evidence linking DPP-4 inhibition to INPPL1-related pathways or skeletal development
- Review of whether other predictions (for example, stiff person syndrome or autoimmune oophoritis) have a stronger biological rationale
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.